title: [Karyotype of peripheral blood lymphocytes in patients treated for Hodgkin disease].
abstract: Peripheral lymphocyte chromosomes were analyzed in 55 consecutive patients with complete remission after treatment for Hodgkin's disease. In 8 patients, observed metaphases were too few in number. The other 47 patients, 29 men and 18 women, had been off all therapy for 53 months (median 41, ext. 1 to 250 months). The mean interval since the diagnosis was 78 months (median: 73 months) and the mean age at the time of chromosome analysis was 38 years (median: 34, ext. 10-78 years). No patient had either a preleukemic syndrome or leukemia. In contrast to karyotypes in normal controls and previously untreated patients, abnormal cells, hypodiploid, hyperdiploid and tetradiploid cells were more frequent. But neither monosomy 5 or 7 nor trisomy 8 were observed. Intrachromosomal rearrangements (gaps, breaks...) were significantly more frequent (12% vs 5% in untreated patients) particularly on chromosomes 1 and 2. Interchromosomal rearrangements were also numerous (1,25%) but no cells showed any specific translocation for malignant hemopathy. Chromosomal aberrations do not seem closely associated with treatments but influenced by the post-diagnosis interval and the factors present at the time of primary treatment.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations / Q000139:chemically induced / Q000187:drug effects; D025063:Chromosome Disorders; D002877:Chromosomes, Human / Q000187:drug effects*; D005260:Female; D006689:Hodgkin Disease / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007621:Karyotyping; D008214:Lymphocytes / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D011003:Ploidies / Q000187:drug effects; D011289:Preleukemia / Q000139:chemically induced; D012306:Risk
chemical_list: D000970:Antineoplastic Agents
vernacular_title: Le caryotype des lymphocytes sanguins périphériques des hodgkiniens traités.